Unique ID issued by UMIN | UMIN000023756 |
---|---|
Receipt number | R000027371 |
Scientific Title | Vascular function and Antiplatelet effects on switching from Clopidgrel to Prasugrel in chronic phase after percutaneous coronary intervention |
Date of disclosure of the study information | 2016/09/01 |
Last modified on | 2016/08/25 00:37:40 |
Vascular function and Antiplatelet effects on switching from Clopidgrel to Prasugrel in chronic phase after percutaneous coronary intervention
Switch-Pras study
Vascular function and Antiplatelet effects on switching from Clopidgrel to Prasugrel in chronic phase after percutaneous coronary intervention
Switch-Pras study
Japan |
The patients on DAPT after PCI who underwent follow-up coronary angiography
Cardiology |
Others
YES
Platelet Reactivity after switching from Clopidgrel with Aspirin to Prasugrel with Aspirin in patients who underwent PCI.
Efficacy
The rate of change on PRU from baseline to observation point(6M+-3M) between Clopidgrel with Aspirin and Prasugrel with Aspirin
1:The effect of CYP2C19 polymorphism against the PRU from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin
2:Quantitative change on FMD from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin
3:Quantitative change on RHI from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin
4:Quantitative change and rate of change on Inflammatory biomarkers from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin
5:Quantitative change on CD34+/CD133+/CD45low cells from baseline to observation point between Clopidgrel with Aspirin and Prasugrel with Aspirin
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
NO
2
Treatment
Medicine |
Clopidgrel with Aspirin group
Aspirin is 81mg X1
Clopidgrel is 75mg X1
Prasugrel with Aspirin group
Aspirin is 81mg X1
Prasugrel is 3.75mg X1
20 | years-old | <= |
85 | years-old | > |
Male and Female
1:The patients on DAPT after PCI who underwent follow-up coronary angiography
2:Patients agreening with this study after informed consent
1:Ptients who has high risk for bleeding
2:Patients with heart Valve Disease and congenital heart disease
3:Patients with cerebrovascular disease
4:Patients who have infection or Inflammatory disease
5:Patients with malignant neoplasm
6:CKD <G4 eGFR<30(ml/min/1.7m2)
7:Patients with allergy against thienopyridines
8:Patients undergoing anticoagulation therapy
9:Patients who are not suitable for this study
100
1st name | |
Middle name | |
Last name | Teruo Inoue |
Dokkyo Medical University
Cardiovascular Medicine
880 Kitakobayashi Mibu Tochigi
0282-86-1111
inouet@dokkyomed.ac.jp
1st name | |
Middle name | |
Last name | Masashi Sakuma |
Dokkyo Medical University
Cardiovascular Medicine
880 Kitakobayashi Mibu Tochigi
0282-86-1111
masakuma@dokkyomed.ac.jp
Department of Cardiovascular Medicine,Dokkyo Medical University
nothing
Self funding
NO
2016 | Year | 09 | Month | 01 | Day |
Unpublished
2015 | Year | 05 | Month | 31 | Day |
2015 | Year | 06 | Month | 30 | Day |
2016 | Year | 08 | Month | 25 | Day |
2016 | Year | 08 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027371
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |